
This study examined the efficacy and toxicity associated with chronic zzso zzso zzso In a series of 68 patients with cancer pain zzso to zzso zzso alone, analgesia was effectively regained by zzso a zzso zzso zzso patients zzso were considered treatment successes, according to conventional zzso Median length of therapy was zzso days, with the longest infusion lasting 277 zzso zzso zzso infusion zzso ranged from zzso to zzso with infusion rates varying from 4 to 18 zzso The majority of patients experienced pain relief with little or no sympathetic or zzso impairment after the first 24 h at zzso zzso of zzso and were managed in home or chronic care settings without the need for zzso In patients receiving higher zzso zzso sympathetic, sensory and motor blockade were well tolerated during chronic zzso zzso loss was consistently observed only at zzso zzso exceeding zzso and motor impairment occurred only at zzso exceeding zzso zzso zzso was observed in 6 patients zzso for the first 24 h only, which supports the requirement for monitoring and fluid therapy during initiation of the zzso zzso No patient experienced zzso or systemic zzso despite plasma total zzso zzso as high as zzso zzso zzso plasma zzso levels were measured in 15 patients during chronic zzso There was considerable zzso and zzso zzso in plasma zzso zzso and zzso zzso We conclude that zzso zzso infusion is an effective and safe technique for long-term administration of analgesics in the zzso cancer zzso 

